Atypical antipsychotics may raise LUTS risk in women

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

A new randomized trial shows Er:YAG laser therapy offers no significant benefit over sham treatment for managing female stress urinary incontinence at 6 months.

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.

In this Q&A, Karyn S. Eilber, MD, shares some of the biggest takeaways from the new AUA/SUFU/AUGS 2025 Guidelines on Genitourinary Syndrome of Menopause.

A new study finds no significant difference in symptom improvement between onabotulinumtoxinA injections and midurethral sling surgery for women with mixed urinary incontinence.